Evaluation of circulating calcitonin: Analytical aspects

被引:10
作者
Martinetti, A [1 ]
Seregni, E [1 ]
Ferrari, L [1 ]
Pallotti, F [1 ]
Aliberti, G [1 ]
Coliva, A [1 ]
Fracassi, S [1 ]
Bombardieri, E [1 ]
机构
[1] Natl Canc Inst, Div Nucl Med, I-20133 Milan, Italy
来源
TUMORI JOURNAL | 2003年 / 89卷 / 05期
关键词
calcitonin; immunoradiometric assays; medullary thyroid carcinomas;
D O I
10.1177/030089160308900525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aim: Calcitonin (hCT) is a useful serum marker for the diagnosis and monitoring of medullary thyroid carcinoma (MTC). However, hCT values provided by different methods may differ, leading to difficulties in the interpretation of hCT results. In this study we compared four immunoradiometric (IRMA) and radioimmunometric (RIA) assays for hCT determination. Material and methods: hCT was measured in 35 patients by means of the following commercially available IRMA or RIA kits: CT US (Biosource), IRMA hCT (Schering-CIS bio international), ultra-sensitive calcitonin (DSL), and calcitonin assay (Scantibodies). A comparison of the distribution of the hCT values measured by the tested IRMA-RIAs and a correlation analysis were performed. Results: The hCT values were widely dispersed and the classification of the patients according to the hCT cutoff value varied depending on the assay used. Conclusion: Despite efforts to develop new, highly specific antibodies, the evaluation of this marker is still flawed by analytical inaccuracy. hCT values are widely dispersed depending on the method used for marker measurement; as a consequence, patient classification according to the hCT cutoff value is still dependent on the assay used.
引用
收藏
页码:566 / 568
页数:3
相关论文
共 11 条
[1]  
Bieglmayer C, 2002, WIEN KLIN WOCHENSCHR, V114, P267
[2]   STRUCTURAL CHARACTERIZATION OF A HIGH-MOLECULAR-MASS FORM OF CALCITONIN [PROCALCITONIN-(60-116)-PEPTIDE] AND ITS CORRESPONDING N-TERMINAL FLANKING PEPTIDE [PROCALCITONIN-(1-57)-PEPTIDE] IN A HUMAN MEDULLARY-THYROID CARCINOMA [J].
CONLON, JM ;
GRIMELIUS, L ;
THIM, L .
BIOCHEMICAL JOURNAL, 1988, 256 (01) :245-250
[3]   Clinical evaluation of a new sensitive calcitonin assay: study of specificity [J].
d'Herbomez, M ;
Leclerc, L ;
Vantyghem, MC ;
Fourrier, F ;
Proye, C ;
Wemeau, JL .
CLINICA CHIMICA ACTA, 2001, 311 (02) :149-155
[4]   CHARACTERIZATION OF THE MAJOR FORMS OF HUMAN CALCITONIN IN TISSUE AND SERUM [J].
DERMODY, WC ;
ROSEN, MA ;
ANANTHASWAMY, R ;
MCCORMICK, WM ;
LEVY, AG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 52 (06) :1090-1098
[5]  
ENGLEBACH M, 2000, J CLIN ENDOCR METAB, V85, P1980
[6]  
GHILLANI PP, 1989, CANCER RES, V49, P6845
[7]   Medullary thyroid carcinoma:: role of genetic testing and calcitonin measurement [J].
Lips, CJM ;
Höppener, JWM ;
Thijssen, JHH .
ANNALS OF CLINICAL BIOCHEMISTRY, 2001, 38 :168-179
[8]   Diagnostic procedures in the follow-up of patients affected by MEN type 2 [J].
Seregni, E ;
Pallotti, F ;
Mattavelli, F ;
Ferrari, L ;
Martinetti, A ;
Aliberti, G ;
Villano, C ;
Castellani, MR ;
Bombardieri, E .
TUMORI JOURNAL, 2003, 89 (05) :563-565
[9]   IMMUNOCHEMICAL HETEROGENEITY OF CALCITONIN IN PLASMA OF PATIENTS WITH MEDULLARY THYROID-CARCINOMA [J].
SIZEMORE, GW ;
HEATH, H .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 55 (05) :1111-1118
[10]  
TOBLER PH, 1983, J CLIN ENDOCR METAB, V57, P749, DOI 10.1210/jcem-57-4-749